Registry-Based Clinical Trials: Expert Meeting Materials Now Available

On March 30, 2016, CTTI’s Registry Trials Project held a multi-stakeholder expert meeting to accomplish the following:

  • Identify essential elements of registries needed to successfully embed and conduct registry-based clinical trials
  • Present findings from the project’s literature review and expert interviews
  • Receive feedback on potential benefits of and existing barriers to the use of registries in clinical trials
  • Reach consensus on best practices to increase adoption of clinical trials within registries

The meeting included more than 40 participants from academia, government agencies, industry, and patient representatives. A key takeaway was that a role exists for registries in creating a sustainable infrastructure to conduct regulatory trials, including early development, pre-market, and post-approval investigations. Suggestions were generated around considerations including data quality, regulatory issues, governance, and registry design. Input from the meeting, along with evidence gathered through the CTTI project, will be used to develop recommendations and tools to increase the value, acceptance, and success of registry-based clinical trials.

CLICK HERE to access the meeting summary, slides, agenda, and other materials.

A Brave New World: Registry-Based Clinical Trials

MARCH 30, 2016

CTTI Project: Registry Trials

Meeting Objectives

  • Identify essential elements of registries needed to successfully embed and conduct registry-based clinical trials
  • Present findings from CTTI’s Registry Trials Project: Literature Review and Expert Interviews
  • Receive feedback on potential benefits of and existing barriers to the use of registries in clinical trials
  • Reach consensus on best practices to increase adoption of clinical trials within registries

Meeting Location:

DoubleTree Silver Spring Hotel by Hilton, 8727 Colesville Road, Silver Spring, MD 20910

The views and opinions expressed in this presentation are those of the individual presenter and should not be attributed to the Clinical Trials Transformation Initiative, or any organization with which the presenter is employed or affiliated.

CTTI Tackles 3 Issues in Clinical Trials with New Projects

At CTTI, we are continuously looking for practices that will increase the quality and efficiency of clinical trials. In 2014, three new topics have been added to our portfolio:

  1. Conducting Trials Using Data Registries: Demographic, disease, and outcome data collected in clinical observational registries often overlap with data gathered for clinical trials. Integrating clinical trials within observational data registries may offer opportunities to avoid duplicative data collection and increase efficiency while decreasing clinical trial costs. Objectives for this project include identifying upfront costs and operational adjustments required to utilize a data registry for a clinical trial, as well as recommending best practices for conducting randomized registry trials.
  2. Data Monitoring Committees (DMCs): As the use of DMCs has increased and evolved over the past 40 years, critical issues have emerged. A few of these issues include differences in DMC roles and responsibilities, which contributes to confusion and unclear expectations, as well as a lack of a clear plan for preparing the next generation of DMC members. Objectives for this project include understanding the current landscape of DMC use and conduct, clarifying the purpose of and rationale for using a DMC, and describing effective communication practices between independent DMCs and other trial stakeholders.
  3. Investigator Turnover: While an enormous amount of time and resources are spent initiating new investigators into the clinical trial process, there continues to be a high turnover rate for investigators. As many as 40% of investigators annually choose not to participate in another FDA-regulated trial. This high rate of attrition impacts site and overall trial performance. Objectives for this project include obtaining a more thorough understanding of the factors that influence investigators’ decisions to leave the clinical research practice, as well as defining the impact of investigator turnover on industry and society.